Puma Biotechnology (NASDAQ:PBYI) Insider Douglas Hunt Sells 3,973 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Douglas Hunt sold 3,973 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $5.84, for a total transaction of $23,202.32. Following the sale, the insider owned 160,921 shares in the company, valued at approximately $939,778.64. This represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Puma Biotechnology Trading Up 1.8%

PBYI stock traded up $0.11 during trading on Thursday, reaching $6.20. 374,316 shares of the stock were exchanged, compared to its average volume of 344,360. The firm has a market capitalization of $312.42 million, a price-to-earnings ratio of 8.38 and a beta of 1.19. Puma Biotechnology, Inc. has a 1 year low of $2.58 and a 1 year high of $6.29. The business has a 50 day moving average price of $5.42 and a 200-day moving average price of $4.77.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.12. Puma Biotechnology had a net margin of 17.45% and a return on equity of 36.17%. The firm had revenue of $54.48 million for the quarter, compared to the consensus estimate of $51.00 million. On average, research analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Analyst Ratings Changes

PBYI has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings lowered Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On Puma Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of Puma Biotechnology by 214.1% during the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 6,450 shares in the last quarter. Cerity Partners LLC acquired a new position in shares of Puma Biotechnology in the 2nd quarter valued at $36,000. BNP Paribas Financial Markets grew its position in shares of Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 2,290 shares during the period. Savant Capital LLC bought a new position in shares of Puma Biotechnology during the 2nd quarter valued at about $44,000. Finally, Ethic Inc. bought a new stake in shares of Puma Biotechnology in the second quarter valued at about $51,000. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.